Anti-HBs Seroprevalence in Blood Donors from Tyrol, Austria
Vaccines (Basel). 2024 Oct 11;12(10):1156. doi: 10.3390/vaccines12101156.
PMID:
Meeting Report From „Correlates of Protection for Next Generation Influenza Vaccines: Lessons Learned From the COVID-19 Pandemic“
Influenza Other Respir Viruses. 2024 Oct;18(10):e13314. doi: 10.1111/irv.13314.
PMID:
Effectiveness of the First and Second Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Dose: A Nationwide Cohort Study From Austria on Hybrid Versus Natural Immunity
Open Forum Infect Dis. 2024 Sep 19;11(10):ofae547. doi: 10.1093/ofid/ofae547. eCollection 2024 Oct.
PMID:
mRNA vaccines for infectious diseases – advances, challenges and opportunities
Nat Rev Drug Discov. 2024 Nov;23(11):838-861. doi: 10.1038/s41573-024-01042-y. Epub 2024 Oct 4.
PMID:
Adjuvant Use of the Invariant-Natural-Killer-T-Cell Agonist α-Galactosylceramide Leads to Vaccine-Associated Enhanced Respiratory Disease in Influenza-Vaccinated Pigs
Vaccines (Basel). 2024 Sep 18;12(9):1068. doi: 10.3390/vaccines12091068.
PMID:
Virology-The next fifty years
Cell. 2024 Sep 19;187(19):5128-5145. doi: 10.1016/j.cell.2024.07.025.
PMID:
Sequential immunization with chimeric hemagglutinin ΔNS1 attenuated influenza vaccines induces broad humoral and cellular immunity
NPJ Vaccines. 2024 Sep 16;9(1):169. doi: 10.1038/s41541-024-00952-7.
PMID:
A recombinant N2 neuraminidase-based CpG 1018® adjuvanted vaccine provides protection against challenge with heterologous influenza viruses in mice and hamsters
Vaccine. 2024 Oct 24;42(24):126269. doi: 10.1016/j.vaccine.2024.126269. Epub 2024 Sep 5.
PMID:
Impact of Pre-Existing Immunity and Age on Antibody Responses to Live Attenuated Influenza Vaccine
Vaccines (Basel). 2024 Aug 1;12(8):864. doi: 10.3390/vaccines12080864.
PMID:
Enhancing NA immunogenicity through novel VLP designs
Vaccine. 2024 Oct 24;42(24):126270. doi: 10.1016/j.vaccine.2024.126270. Epub 2024 Aug 27.
PMID: